ClinicalTrials.gg
CompletedNCT03995888Updated Feb 12, 2026Results posted

Assessing Radio-hybrid Prostate Specific Membrane Antigen (rhPSMA-7.3) (18F) in Healthy Volunteers and Subjects With Prostate Cancer

A Phase 1 interventional study of rhPSMA-7.3 (18F) Injection in Prostate Cancer, sponsored by Blue Earth Diagnostics. Completed at 1 site in Finland. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-12.

Sponsored by Blue Earth Diagnostics (part of Bracco) · Phase 1, Interventional, and Diagnostic

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing flotufolastat F 18 in Prostatic Neoplasms — 6 open to participants now, 7 under way, 2 of them phase 3. flotufolastat F 18 · Prostatic Neoplasms.

Enrollment
12th of 15
24 · median 70
Started
2019
the only one that year
Phase 1
3 of 15
none open now
Registered
1st of 15
by date
Lead sponsor
4 of 15
Blue Earth Diagnostics

Among the 15 studies testing flotufolastat F 18 in Prostatic Neoplasms, this one is the 12th largest by enrollment, is the only one that started in 2019, is one of 3 in phase 1, and was the 1st registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

6 of the 15 studies testing flotufolastat F 18 in Prostatic Neoplasms are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About flotufolastat F 18

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing flotufolastat F 18 in Prostatic Neoplasms, or all of them as a file.
02

Study summary

A Phase 1, Open-label Study to Assess Safety, Biodistribution, and Internal Radiation Dosimetry of rhPSMA-7.3 (18F) Injection in Healthy Volunteers, and to Assess Safety and Investigate the Imaging Characteristics in Subjects With Prostate Cancer.

03

Conditions studied

  • Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria: Healthy Volunteers

  1. Male and females 21-65 years.
  2. Clinically acceptable medical history

Key Exclusion Criteria: Healthy Volunteers

  1. Received ionising radiation exposure from clinical trials or medical examinations or treatment in the last 12 months.
  2. Suffers from claustrophobia.
  3. Bilateral hip prostheses.

Key Inclusion Criteria: Patients

  1. Male 18-80 years.
  2. confirmed adenocarcinoma of the prostate
  3. Clinically acceptable medical history
  4. (ECOG) performance status 0-2

Key Exclusion Criteria: Patients

  1. 28 days prior to enrollment.
  2. Extensive disease.
  3. Underlying disease which might confound interpretation.
  4. Bilateral hip prostheses.
  5. High energy (>300 Kiloelectron Volt (keV)) gamma-emitting radioisotope administered within five physical half-lives, or any intravenous iodinated contrast medium within 24 hours, or any high density oral contrast medium (oral water contrast is acceptable) within 5 days prior to study drug administration.
  6. X-ray contrast agent (\<24 hr for intravenous agents and \<5 days for oral agents).
  7. History of claustrophobia.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 1
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Healthy Volunteers

    Single intravenous administration of rhPSMA-7.3 (18F) for PET Scan

    Drug: rhPSMA-7.3 (18F) Injection

  • Experimental
    Patients

    Single intravenous administration of rhPSMA-7.3 (18F) for PET Scan

    Drug: rhPSMA-7.3 (18F) Injection

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events as Classified by MedDRA

    Safety will be assessed from data on the occurrence of one or more treatment-emergent Adverse Events from the time of intravenous administration of 18F-rhPSMA-7.3 throughout the study period, and changes in serum biochemistry, hematology, coagulation, urinalysis, vital signs, Electrocardiogram (ECG), injection site status, and physical examination findings.

    Time frame: 1 month

07

Results

Posted Feb 12, 2026

Participant flow

This study was conducted between 11 June 2019 (first subject, screening visit) and 16 April 2020 (last subject, last visit) at a single site in Finland. Of the 24 potential subjects screened, 16 met all the study eligibility criteria (six healthy volunteers and 10 subjects with prostate cancer). Five subjects were considered screen failures and three subjects were not assigned to IMP as they were back-up subjects who were subsequently not required for PET imaging.

Participant flow — Overall Study
MilestoneHealthy VolunteersProstate Cancer Cohort AProstate Cancer Cohort BProstate Cancer Cohort C
Started6334
Completed6334
Not completed0000

Outcome measures

PrimaryNumber of Participants With Treatment-emergent Adverse Events as Classified by MedDRA

Safety will be assessed from data on the occurrence of one or more treatment-emergent Adverse Events from the time of intravenous administration of 18F-rhPSMA-7.3 throughout the study period, and changes in serum biochemistry, hematology, coagulation, urinalysis, vital signs, Electrocardiogram (ECG), injection site status, and physical examination findings.

Time frame:
1 month
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events as Classified by MedDRA
ParticipantsHealthy VolunteersProstate Cancer Cohort AProstate Cancer Cohort BProstate Cancer Cohort C
Number of Participants With Treatment-emergent Adverse Events as Classified by MedDRA2212

Adverse events

Collected over As specified in the Statistical Analysis Plan, results are presented as only those treatment-emergent adverse events which occurred up to 1 Month after the 18F administration. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Healthy Volunteers0/6 (0%)0/6 (0%)2/6 (33.3%)
Prostate Cancer Cohort A0/3 (0%)1/3 (33.3%)1/3 (33.3%)
Prostate Cancer Cohort B0/3 (0%)0/3 (0%)1/3 (33.3%)
Prostate Cancer Cohort C0/4 (0%)1/4 (25%)1/4 (25%)
Most frequent serious events
Most frequent serious events
EventHealthy VolunteersProstate Cancer Cohort AProstate Cancer Cohort BProstate Cancer Cohort C
Retention of urineRenal and urinary disorders0/61/30/30/4
Neutropenic infectionInfections and infestations0/60/30/31/4
Most frequent other events
Most frequent other events
EventHealthy VolunteersProstate Cancer Cohort AProstate Cancer Cohort BProstate Cancer Cohort C
HeadacheNervous system disorders2/61/30/30/4
Aspartate aminotransferase increasedInvestigations0/60/31/30/4
ContusionInjury, poisoning and procedural complications0/60/30/31/4
DizzinessNervous system disorders1/60/30/30/4
SinusitisInfections and infestations1/60/30/30/4
Hepatic lesionHepatobiliary disorders1/60/30/30/4

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Healthy VolunteersProstate Cancer Cohort AProstate Cancer Cohort BProstate Cancer Cohort CTotal
Median62 (25 to 64)55 (55 to 56)69 (67 to 80)73 (65 to 76)64 (25 to 80)
Sex: Female, Male
Sex: Female, Male(Participants)Healthy VolunteersProstate Cancer Cohort AProstate Cancer Cohort BProstate Cancer Cohort CTotal
Female333413
Male30003
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Healthy VolunteersProstate Cancer Cohort AProstate Cancer Cohort BProstate Cancer Cohort CTotal
Hispanic or Latino00000
Not Hispanic or Latino633416
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(participants)Healthy VolunteersProstate Cancer Cohort AProstate Cancer Cohort BProstate Cancer Cohort CTotal
Finland633416
Height (cm
Height (cm(Centimeters (cm))Healthy VolunteersProstate Cancer Cohort AProstate Cancer Cohort BProstate Cancer Cohort CTotal
Median175.25 (160 to 186)177.50 (172 to 180)174 (172 to 176.5)171.75 (160 to 184)173.27 (160 to 186)
Weight (kg)
Weight (kg)(Kilograms (kg))Healthy VolunteersProstate Cancer Cohort AProstate Cancer Cohort BProstate Cancer Cohort CTotal
Median79.15 (66.5 to 89.8)81.80 (71.0 to 87.5)82.70 (75.5 to 83.5)79.40 (77.5 to 99.0)80.50 (66.5 to 99.0)
Body Mass Index (kg/m2)
Body Mass Index (kg/m2)(Kilograms/meters squared [kg^m2])Healthy VolunteersProstate Cancer Cohort AProstate Cancer Cohort BProstate Cancer Cohort CTotal
Median25.25 (23.2 to 30.0)27.70 (21.8 to 27.8)26.50 (25.5 to 27.6)28.45 (26.0 to 30.4)27.05 (21.8 to 30.4)
Eastern Cooperative Oncology Group (ECOG)
Eastern Cooperative Oncology Group (ECOG)(participants)Healthy VolunteersProstate Cancer Cohort AProstate Cancer Cohort BProstate Cancer Cohort CTotal
0—3328
1—0022
08

Study locations

1 site
  • Clinical Research Services Turku - CRST Oy
    Turku, FI-20520, Finland
09

References and documents

Publications

  • Malaspina S, Oikonen V, Kuisma A, Ettala O, Mattila K, Bostrom PJ, Minn H, Kalliokoski K, Postema EJ, Miller MP, Scheinin M. Kinetic analysis and optimisation of 18F-rhPSMA-7.3 PET imaging of prostate cancer. Eur J Nucl Med Mol Imaging. 2021 Oct;48(11):3723-3731. doi: 10.1007/s00259-021-05346-8. Epub 2021 Apr 12. PubMed 33846844 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2019 to primary completion in Apr 2020, 10 months.

Results were first posted in Feb 2026, 5 years 9 months after primary completion.

Of 212 industry-sponsored phase 1 interventional studies under Prostatic Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's 10 months is below that.

Counting every sponsor, half of 456 studies reached it within 43 months; a quarter within 23 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2019
First posted
Jun 24, 2019
StartActual
Jun 11, 2019
Primary completionActual
Apr 16, 2020
CompletionActual
Apr 16, 2020
Results first posted
Feb 12, 2026
Last update
Feb 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03995888
Responsible party
Sponsor
First posted
Jun 24, 2019
Start date
Jun 11, 2019
Primary completion
Apr 16, 2020
Completion
Apr 16, 2020
Results posted
Feb 12, 2026
Last update
Feb 12, 2026

Study contacts

Mika Scheinin
principal investigator · Clinical Research Services Turku - CRST Oy

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Flotufolastat F 18

Start the discussion